Bioxcel Therapeutics's 15min chart shows KDJ Death Cross and Bearish Marubozu.

Bioxcel Therapeutics's 15-minute chart has recently triggered a KDJ Death Cross and a Bearish Marubozu, which indicates a shift in the momentum of the stock price towards a downward trend. This suggests that there is a potential for further decreases in the stock price, as sellers are currently controlling the market. The bearish momentum is likely to continue in the near future.

Bioxcel Therapeutics Inc. (BTAI) shares experienced a notable drop following the recent release of its 15-minute chart, which triggered a KDJ Death Cross and a Bearish Marubozu. This technical analysis suggests a shift in the stock's momentum towards a downward trend, indicating potential further decreases in the stock price. Sellers currently appear to be controlling the market, with the bearish momentum likely to continue in the near future.

Despite the recent regulatory milestones, such as positive feedback from the FDA regarding the sNDA submission for BXCL501, the stock's downward trajectory is evident. The FDA's positive comments, received during a pre-sNDA meeting, have bolstered Bioxcel's confidence in its planned submission for BXCL501, a treatment aimed at managing agitation associated with bipolar disorders or schizophrenia [1]. However, the stock's volatility and recent technical indicators suggest a cautious approach for investors.

The FDA's positive response on the sNDA submission indicates alignment on the content and format of the submission, which is now on track for submission in the first quarter of 2026. The pre-sNDA meeting, originally scheduled for August 20, 2025, was deemed unnecessary after receiving the preliminary comments from the FDA on August 14, 2025 [1]. The feedback will serve as the official record for the meeting.

The primary focus of the pre-sNDA meeting was to gain alignment with the FDA regarding the content and format of the sNDA submission for the at-home (outpatient) use of BXCL501. The FDA's approval of the planned submission reflects a shared commitment to addressing the urgent needs of patients suffering from agitation.

The positive FDA feedback is a significant milestone for Bioxcel Therapeutics, as it brings the company closer to bringing a safe and effective outpatient treatment to patients suffering from agitation. This development has the potential to transform the treatment paradigm for bipolar disorder and schizophrenia.

However, the stock's recent performance and technical indicators suggest a potential downturn. The stock price gained 3.47% on the last trading day (Monday, 18th Aug 2025), rising from $5.48 to $5.67. During the last trading day, the stock fluctuated 25.46% from a day low at $5.46 to a day high of $6.85 [2]. The price has risen in 8 of the last 10 days and is up by 123.23% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 26 million more shares were traded than the day before. In total, 34 million shares were bought and sold for approximately $190.92 million [2].

The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 70.18% during the next 3 months and, with a 90% probability hold a price between $3.18 and $11.89 at the end of this 3-month period [2].

The Bioxcel Therapeutics Inc. stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $5.53 and $2.70. A breakdown below any of these levels will issue sell signals [2].

However, the recent KDJ Death Cross and Bearish Marubozu suggest a shift in the momentum towards a downward trend. This indicates a potential for further decreases in the stock price, as sellers are currently controlling the market. The bearish momentum is likely to continue in the near future.

References:
[1] https://www.ainvest.com/news/bioxcel-therapeutics-stock-surges-fda-positive-meeting-comments-2508/
[2] https://stockinvest.us/stock/BTAI